JANX:NASDAQ, Janux Therapeutics, Inc.
JANX stock overview
Janux Therapeutics, Inc. (JANX:NASDAQ) closed at $10.08 on November 20, 2026,
down 2.04% on the day.
The stock trades 71.5% below its 52-week high of $35.34
and 0.3% above its 52-week low of $10.05.
Over the past year, it lost 68.0%.
Janux Therapeutics, Inc. is part of the Health Care sector.
Key figures
- Price
- $10.08
- Day change
- -2.04%
- Volume
- 1,114,707
- Average volume
- 952,264
- Market cap
- 616M+
- 52-week range
- $10.05 – $35.34
- 50-day average
- $16.10
- 200-day average
- $15.30
Price action over the past year
In 252 trading sessions since November 20, 2025, JANX closed higher on 123 days (49%).
Its best day was January 22, 2026 (+14.09%) and its worst was December 2, 2025 (-53.34%).
The stock moved 10% or more in a single session 5 times.
Recent signals
JANX news
-
Nov 10, 2026:
Janux Therapeutics Stock In Focus As Loss Narrows And Phase 1 Data Nears
-
Nov 9, 2026:
Janux Reports Deep B-Cell Depletion in Initial Phase 1 Trial of JANX011; Shares Fall
-
Nov 9, 2026:
Janux Therapeutics Announces Positive Initial Phase 1 Data for JANX011 in Healthy Volunteers, Supporting Planned Development in Patients with Autoimmune Disease
-
Nov 7, 2026:
Janux Therapeutics (JANX) Earnings Beat Brings Its Pricey Valuation Back Into Focus
-
Nov 5, 2026:
Janux Therapeutics, Inc. (JANX) Reports Q3 Loss, Beats Revenue Estimates
-
Nov 5, 2026:
Janux Therapeutics Reports Third Quarter 2026 Financial Results and Business Highlights
-
Nov 2, 2026:
Janux Therapeutics to Host Virtual Event Presenting Initial Phase 1 Clinical Data for JANX011 in Healthy Volunteers
-
Oct 29, 2026:
Janux Therapeutics (JANX) Stock Looks Above Fair Value Based On Sales
About Janux Therapeutics, Inc.
Janux Therapeutics Inc is an innovative biopharmaceutical company developing next-generation therapeutics based on proprietary tumor activated T Cell Engager platform technology to better treat patients suffering from cancer.
Similar stocks
Find more stocks like JANX with the
Spikes,
Gaps,
Breakouts and
Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.